ASX cannabis share Cronos has soared 80% in a month. What's going on?

This cannabis share has been on fire this month…

| More on:
Back view of a man lifting hish hands high in front of hemp plants grown for cannabis.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It has been a stunning few weeks for the Cronos Australia Ltd (ASX: CAU) share price.

Since this time last month, the medicinal cannabis company's shares have risen over 80%.

This led to the Cronos Australia share price reaching a record high of 75 cents earlier today.

Why is the Cronos Australia share price on fire this month?

While the company released a positive update last week which boosted its shares, the majority of the gains were made earlier in the month.

The catalyst for that appears to have been a bullish broker note out of Bell Potter.

According to the note from 5 September, the broker initiated coverage on the company's shares with a buy rating and 60 cents price target.

At the time, the Cronos Australia share price was fetching 46 cents, so this implied potential upside of 30% for investors.

Why is Bell Potter bullish?

Bell Potter explained that its bullish view was based largely on the company's leadership position in medicinal cannabis distribution. It commented:

Cronos Australia is a medicinal cannabis company that is the market leader in distribution to pharmacies and provides patient consulting services through its clinic business. The key driver for the impressive growth in the past 24 months has been the CanView platform which provides the widest range of medicinal cannabis products compared to competitors (Anspec, Health House).

In addition, Bell Potter points out that Cronos Australia is profitable and even pays a dividend. That makes it the only one of its kind in the Australian cannabis industry. It explained:

We initiate coverage on Cronos with a Buy recommendation. We expect the momentum observed in FY22 to continue into FY23 and translate into strong revenue and earnings growth. Cronos is currently the only profitable dividend paying medicinal cannabis company on the ASX and the valuation does not appear demanding relative to the expected growth.

Though, with the Cronos Australia share price now trading higher than Bell Potter's valuation, it's worth considering that it could have peaked for the time being.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Cannabis Shares

Man in the green house growing medical cannabis
Cannabis Shares

ASX cannabis stocks eyeing $1 billion domestic market

Legal cannabis use is soaring in Australia.

Read more »

two men in formal business clothing closely inspect a bud from a cannabis crop.
Cannabis Shares

2 ASX cannabis shares with big news today

What's going on with these pot stocks today? Let's find out.

Read more »

A man in a horse head mask and suit jumps for joy on a beach.
Cannabis Shares

Could ASX cannabis shares be set for a smoking hot rebound?

ASX cannabis stocks could be set for a strong finish to 2024.

Read more »

Man in a cannabis greenhouse looks unhappy and puts his thumb down.
Cannabis Shares

Why are these 2 ASX cannabis stocks sputtering today?

Up 174% in 2023, this ASX cannabis share is giving back some more of its gains today.

Read more »

A young male investor wearing a white business shirt screams in frustration with his hands grasping his hair after ASX 200 shares fell rapidly today and appear to be heading into a stock market crash
Cannabis Shares

Guess which ASX cannabis share is crashing 36% following an FDA blow

Rookie mistake: This cannabis share just missed out on FDA approval for a simple reason.

Read more »

A Cronos Australia farmer and ASX cannabis shares investor stands in a field of cannabis plants and smiles at the camera
Cannabis Shares

Could ASX cannabis shares be set for a resurgence?

The world's legal and medical fraternities are taking small steps forward in the medicinal cannabis movement.

Read more »

A young woman holding her phone smiles broadly and looks excited, after receiving good news.
Cannabis Shares

This ASX cannabis stock is up 160% since June, and it has an FDA ruling coming up!

Investors are very excited about this cannabis stock.

Read more »

two men in formal business clothing closely inspect a bud from a cannabis crop.
Cannabis Shares

Why ASX cannabis shares just jumped back into the spotlight

ASX cannabis shares operate in a nation where medical marijuana is legal but recreational use remains broadly forbidden.

Read more »